Baroda BNP Paribas Value Fund
The scheme seeks to generate long-term capital appreciation from a diversified portfolio of predominantly equity and equity related instruments by following a value investment strategy.
Growthvine rating: 2/5 — ranked #19 of 24 in category.
Fund basics
| Category | Equity: Value |
|---|
| NAV | ₹13.03 (as of 2026-10-01) |
|---|
| AUM | ₹993 Cr |
|---|
| Expense ratio | 1.92% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ankeet Pandya |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 1 year |
|---|
Performance & risk
| Sharpe ratio | 0.32 |
|---|
| Standard deviation | 15.11% |
|---|
| Max drawdown | −20.14% |
|---|
| Alpha | -1.87 |
|---|
| Beta | 0.96 |
|---|
Over 5 years, captured 92.2% of Nifty 500's upside and 101.3% of its downside.
Market cap allocation
| Large cap | 69.7% |
|---|
| Mid cap | 20.2% |
|---|
| Small cap | 10.1% |
|---|
Concentration
| Top 5 holdings | 23.8% |
|---|
| Top 10 holdings | 39.2% |
|---|
| Total holdings | 51 |
|---|
| Index overlap | 37.4% |
|---|
| Active share | 62.6% |
|---|
Top holdings
- ICICI Bank Ltd. — 5.3%
- Reliance Industries Ltd — 5.1%
- Clearing Corporation of India Ltd — 5.1%
- HDFC Bank Ltd. — 5.0%
- Bharat Heavy Electricals Ltd. — 4.5%
- Larsen & Toubro Limited — 3.9%
- Divis Laboratories Ltd. — 3.8%
- GE Vernova T&D India Limited — 3.8%
- Sun Pharmaceutical Industries Ltd. — 2.7%
- Torrent Pharmaceuticals Ltd. — 2.6%
Top sectors
- Banking & Financial — 19.0%
- Pharma & Biotech — 12.9%
- Automobile — 8.3%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −8.3% | Q3 | #16 of 23 |
| 2025 | 1.8% | Q4 (Bottom) | #19 of 22 |
| 2024 | 14.8% | Q4 (Bottom) | #19 of 21 |